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The increased incidence over the past decade of bloodstream infections (BSIs) caused by gram-positive bacteria,
particularly methicillin-resistant Staphylococcus aureus, highlights the critical need for a consistent approach
to therapy. However, there is currently no international consensus on the diagnosis and management of gram-
positive BSIs. The Clinical Consensus Conference on Gram-Positive Bloodstream Infections was convened as
a session at the 9th International Symposium on Modern Concepts in Endocarditis and Cardiovascular In-
fections held in 2007. Participants discussed various aspects of the practical treatment of patients who present
with gram-positive BSI, including therapeutic options for patients with BSIs of undefined origin, the selection
of appropriate empirical therapy, and treatment of complicated and uncomplicated BSIs. The opinions of
participants about these key issues are reflected in this article.
Despite the increasing importance of gram-positive
bacterial infections [1, 2] and, in particular, the clinical
problems related to methicillin-resistant Staphylococcus
aureus (MRSA) bacteremia [3–5], there is no interna-
tional consensus on the diagnosis and management of
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gram-positive bloodstream infections (BSIs). This ar-
ticle summarizes the findings of the Clinical Consensus
Conference on Gram-Positive Bloodstream Infections,
which convened as a session at the 9th International
Symposium on Modern Concepts in Endocarditis and
Cardiovascular Infections held in June 2007. The ob-
jectives were to poll the opinions of participants and
to provide an open forum to discuss practical aspects
of the clinical management of gram-positive BSIs.
Three “state-of-the-art” presentations were given;
these focused on the clinical microbiology of gram-
positive BSI, patient groups at particular risk of de-
veloping gram-positive BSIs, and the management of
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Infectious diseases 75 (45)
Cardiology 30 (18)
Clinical microbiology 18 (11)
Academic research 15 (9)
Microbiology 12 (7)
Pharmaceutical industry 10 (6)
Surgery 4 (2)
Dental medicine 2 (1)
Geographic region




Southern Europe 15 (8)
Benelux 13 (7)
Eastern Europe 13 (7)
Middle East 11 (5)
Italy 9 (5)












NOTE. Data on specialty were available for 166 participants, data on geo-
graphic region were available for 177 participants, and data on age were avail-
able for 160 participants.
gram-positive BSIs, with special reference to S. aureus bacter-
emia. The presentations were followed by a discussion among
conference participants and an international panel of experts
in the diagnosis and treatment of BSIs and their associated
complications. Consensus opinion was not necessarily sought
from participants. This article reflects the outcomes of the dis-
cussion and the results of an integral keypad voting process
with both open and predefined questions and answers.
METHODS
Participants were asked to respond to a series of multiple-choice
questions by selecting 1 answer from a numbered selection of
2–6 possible responses. Answers were registered using series 8
VGD1.01 keypads (provided by Key Audio Visual), which were
distributed to unallocated seats before the admittance of par-
ticipants. To vote, each participant pressed the number that
corresponded to their chosen answer. The display on the keypad
prompted each participant to vote and displayed their vote.
Participants were able to change their vote during the voting
period of 10 s by pressing “C” on the keypad and re-entering
their vote. After an explanation of the voting process, partic-
ipants were familiarized with the operation of the keypads (in-
cluding brief details on the time allocated for voting and the
attribution of answers to individual keypads) with use of a test
question (the response to this test question was not included
in the analyses).
All questions were predetermined by an expert panel, which
included the invited speakers. Three initial questions requested
the age, specialty, and country of work of the participants.
Additional questions were displayed after each of the 3 pre-
sentations, and visual voting cues were displayed before each
set of questions, in addition to the chairman’s instructions. The
scores for each of the responses were displayed as percentages
of the total number of evaluable votes. After keypad voting,
sessions were open to discussion, and although not quantitative,
viewpoints that were expressed during this discussion are in-
cluded in Results.
RESULTS
Participant demographic characteristics. A total of 206 phy-
sicians participated in the conference, the discussion, and the
keypad voting. The mean number of responses per question
was 167 (range, 153–179 responses per question). The key de-
mographic characteristics of the participants are summarized
in table 1. The main specialties were infectious diseases (75
respondents [45%]), cardiology (30 [18%]), and microbiology
(clinical, 18 [11%]; unspecified, 12 [7%]), and the majority
(119 [71%]) of respondents were European.
Defining a clinically relevant BSI. In general, a single
blood culture positive for gram-positive pathogenic bacteria
was considered to be insufficient evidence of a clinically relevant
BSI. A small majority (99 [59%]) of respondents required the
presence of clinical signs of infection or an additional inde-
pendent positive blood culture result to secure a diagnosis of
a clinically relevant infection (figure 1, top). However, there
was general agreement that any blood culture positive for S.
aureus should be regarded as relevant because of the intrinsic
pathogenicity of this organism in the bloodstream and the high
number and frequency of complications associated with S. au-
reus BSIs. In addition, 35 respondents (23%) suggested that the
definition of a clinically relevant BSI will vary depending on
the causative pathogen (figure 1, top).
In the case of a suspected S. aureus BSI, approximately two-
thirds of respondents agreed that the initial diagnostic exam-
ination should include at least 1 laboratory test or imaging
technique, in addition to a full blood profile, blood culture,
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Figure 1. The definition and diagnosis of a clinically relevant bloodstream infection (BSI). Top, Percentage of responses to the following question:
after a blood culture positive for gram-positive pathogenic bacteria, which of the following satisfies your definition of a clinically relevant BSI: (A)
the single blood culture, with no clinical signs of infection; (B) an additional independent blood culture, with no clinical signs of infection; or (C) the
single blood culture plus clinical signs of infection? A total of 153 participants responded to this question. Bottom, Percentage of responses to the
following question: in addition to a full blood profile, blood culture, bacterial identification, and susceptibility testing, what should be included in the
initial standard diagnostic examination for suspected Staphylococcus aureus BSI? Methicillin-resistant S. aureus (MRSA) screening methods included
PCR and other fast laboratory tests. A total of 165 participants responded to this question.
bacterial identification, and susceptibility testing. Of these re-
spondents, 28 (17%) responded that screening for MRSA with
use of rapid laboratory tests, such as PCR, should be included,
and approximately one-half (85 [51.5%]) responded that a
combination of inflammatory markers, imaging techniques,
and MRSA screening should be included (figure 1, bottom).
Some participants suggested that definitions of clinically rele-
vant infection should encompass a range of clinical parameters
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Figure 2. Treatment initiation for a bloodstream infection (BSI) of unknown origin. Top, Percentage of responses to the following question: in your
experience, for what proportion of Staphylococcus aureus BSIs does the source remain unknown despite extensive diagnostics? A total of 158
participants responded to this question. Bottom, Percentage of responses to the following question: would you delay treatment initiation in the case
of either a blood culture positive for S. aureus or for a non–Staphylococcus aureus gram-positive organism because the source of infection is unknown?
A total of 158 participants responded to this question.
that would be applicable to the individual patient and useful
for epidemiological purposes.
BSIs of unknown source. Although establishment of the
probable source of infection may facilitate the selection of an
appropriate intervention and enable monitoring of the effect
of treatment, it is not always possible. In the experience of 158
respondents (68%), the source of S. aureus BSI remained un-
known in 120% of cases, despite extensive diagnostic proce-
dures (figure 2, top). There was an overwhelming consensus
(158 respondents [90%]) that, in the case of a blood culture
positive for S. aureus, treatment initiation should not be delayed
because the source of infection is unknown. However, when
participants considered blood cultures negative for S. aureus
but positive for another gram-positive organism, only 68 re-
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spondents (43%) thought that treatment should never be de-
layed when the source was unknown, and 65 (41%) reported
that the decision to initiate therapy should take into account
the patient’s condition (figure 2, bottom). It was reasoned that,
because patients may be bacteremic for some time before pre-
sentation of clinical symptoms, bacteremia might be indicative
of a deep-seated infection.
Preferred antibiotic treatments for BSIs. Participants were
asked to consider the factors that are most likely to trigger
empirical anti-MRSA therapy for a suspected S. aureus infec-
tion. Individual clinical risk factors were most likely to trigger
empirical treatment against MRSA for 75 respondents (45%),
whereas 65 (39%) reported that local epidemiology was the
primary trigger (figure 3, top). A small proportion (22 [13%])
of respondents reported that MRSA was always assumed in
cases of suspected S. aureus infection; 20 (90%) of these par-
ticipants were from regions with a high prevalence of MRSA
infection.
The majority (144 [86%]) of respondents preferred b-lactams
as the backbone antibiotic regimens directed against methicillin-
susceptible S. aureus (MSSA) infections, whereas glycopeptides
were the anti-MSSA agent of choice for 10 respondents (6%)
(figure 3, bottom). Glycopeptides were the preferred backbone
of antibiotic regimens directed against MRSA infections for 127
respondents (76%).
For empirical therapy of suspected nonstaphylococcal gram-
positive BSI, b-lactams were the agents of choice for the ma-
jority (125 [75%]) of respondents; glycopeptides and fluoro-
quinolones were selected by a minority (23 [14%] and 7 [4%],
respectively) of respondents (figure 3, bottom). Daptomycin was
the backbone of preferred antimicrobial regimens for 23 re-
spondents (14%) for treatment of MRSA BSIs and for 10 re-
spondents (6%) for treatment of MSSA infections.
The treatment of uncomplicated S. aureus BSIs. Partic-
ipants were unable to reach consensus on a definition of un-
complicated S. aureus bacteremia; 45 respondents (27%) sug-
gested that uncomplicated S. aureus bacteremia does not exist.
However, despite the failure to reach consensus, criteria for
defining uncomplicated S. aureus bacteremia were proposed.
This definition required the patient to have catheter-associated
infection, with negative results of a follow-up blood culture; to
defervesce within 72 h after initiation of therapy; to have nor-
mal transesophageal echocardiography (TEE) findings; to be
free of prosthetic material in the joints or cardiovascular space;
and to lack any clinical evidence suggestive of metastatic
infection.
The majority (119 [71%]) of respondents preferred mono-
therapy for uncomplicated S. aureus BSIs (figure 4, top). How-
ever, a substantial minority (37 [22%]) of respondents preferred
combination therapy with 2 agents (including an aminogly-
coside), which alluded to the usefulness of increased cidal ac-
tivity. The voting results suggested that the standard duration
of treatment for uncomplicated S. aureus BSIs was 7–14 days
for 79 respondents (45%), whereas 69 respondents (39%) pre-
ferred treatment for 15–21 days (figure 4, bottom). However,
it was noted that there are no clinical data to demonstrate that
a 7-day course of treatment is equivalent to 14 days of therapy,
and after discussion, there appeared to be consensus favoring
treatment for 14 days.
Complications of BSI. Because S. aureus BSIs are frequently
associated with infective endocarditis (IE), participants were
polled about their use of TEE for patients with S. aureus BSI.
Forty-one percent of physicians reported that they routinely
performed TEE for all patients with S. aureus BSI; many of
these physicians thought that TEE was a cost-effective method
for the determination of the duration of treatment for patients.
Of the remaining 99 respondents (59%), some assessed the
probability of a patient having endocarditis or waited for the
results of transthoracic echocardiography, whereas others de-
ferred the decision to a cardiologist.
Monitoring treatment success of patients with BSI. In ad-
dition to the clinical progress of the patient, for the majori-
ty (139 [82%]) of respondents, blood culture was the best
method to monitor treatment response, although follow-up
blood culture was not always deemed necessary, depending on
the microorganisms involved. However, in the case of S. aureus
infection, follow-up blood cultures were considered to be man-
datory. The majority (98 [58%]) of respondents considered
that, in addition to blood cultures, inflammatory markers, such
as C-reactive protein and procalcitonin, could be important
tools for monitoring clinical progress (figure 5).
DISCUSSION
S. aureus is a leading cause of BSIs [6], and the management
of such infections continues to present a number of significant
challenges to the treating physicians. The initial clinical features
of S. aureus BSIs are often nonspecific, and the patient may be
asymptomatic [7]. In addition, signs of sepsis (e.g., hypother-
mia and hypotension) exist beyond the classic symptom of fever
[8]; thus, a sizeable number of patients have positive blood
culture results in the absence of fever (G.R.C., personal com-
munication). The indication for performing a blood culture in
the absence of clinical signs of infection was therefore ques-
tioned. Of no surprise, the majority of participants considered
a single positive blood culture result to be insufficient evidence
of a clinically relevant BSI. There was, however, recognition
that the definition of a clinically relevant BSI might vary de-
pending on the causative pathogen. For example, coagulase-
negative staphylococci (CoNS) are an important cause of BSIs,
but they are also the most common contaminant of blood
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Figure 3. Comparison of treatment preferences for suspected and confirmed bloodstream infections (BSIs). Top, Percentage of responses to the
following question: which factors are most likely to trigger empirical anti–methicillin-resistant Staphylococcus aureus (MRSA) treatment in a patient
with suspected S. aureus BSI? Bottom, Percentage of responses to the following question: what forms the backbone of your preferred empirical
treatment regimen for suspected non-Staphylococcus gram-positive BSIs, confirmed methicillin-susceptible S. aureus (MSSA) BSIs, and confirmed MRSA
BSIs?
cultures [9, 10]. In a recent report that evaluated the signifi-
cance of 405 CoNS blood culture isolates, 78% of CoNS isolates
were judged to be contaminants [9]. Because of the possibility
of recovering 2 independent CoNS contaminants from a pa-
tient, CoNS isolates should be identified to the species level,
and genotypic analysis should be used in selected cases to de-
termine whether the strains are identical or different.
By agreeing that all blood cultures positive for S. aureus
should be treated as clinically relevant, participants appeared
to support the notion that some other microorganisms should
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Figure 4. Treatment of an uncomplicated Staphylococcus aureus bloodstream infection (BSI). Top, Percentage of responses to the following question:
which best describes your preferred regimen for uncomplicated S. aureus BSIs? A total of 167 participants responded to this question. Bottom,
Percentage of responses to the following question: what is your usual standard treatment duration for uncomplicated S. aureus BSIs? A total of 176
participants responded to this question.
be regarded as categorical pathogens. This is reflective of the
significant pathology associated with S. aureus BSIs if they are
left untreated or are misdiagnosed. Complications include se-
rious metastatic infection, sepsis, and mortality; therefore, ac-
curate diagnosis with use of both traditional and modern tech-
niques is recommended [7].
A substantial proportion of participants felt that inflam-
matory markers were a valuable addition to blood cultures for
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Figure 5. Parameters for treatment success in gram-positive bloodstream infections (BSIs). The participants were asked: in addition to the clinical
progress of the patient, which is the best parameter of treatment success for gram-positive BSIs? A total of 169 participants responded to this
question.
the evaluation of treatment success. Both C-reactive protein
and procalcitonin have demonstrated high sensitivity when
used as indices of therapeutic success [11, 12]. In addition,
recent data suggest that serial monitoring of procalcitonin levels
may have health care–related economic benefits, because it en-
ables an earlier discontinuation of antibiotic therapy [13]. Not-
withstanding, the potential of these markers to complicate
rather than assist in the assessment of treatment success was
highlighted. Elevation of the C-reactive protein level, for ex-
ample, can occur in the context of conditions other than in-
fection; in addition, the C-reactive protein level may remain
elevated in patients after resolution of infection. Publications
regarding the diagnostic and prognostic use of procalcitonin
level measurement are contradictory. Furthermore, patient
characteristics and clinical settings vary markedly, and the data
have been difficult to interpret and are often extrapolated in-
appropriately to clinical use. Although high levels of procal-
citonin occur frequently in infection, the procalcitonin level is
also elevated in some noninfectious conditions. Thus, procal-
citonin level is not a specific indicator of either infection or
BSI [14].
Published studies of S. aureus bacteremia report an undefined
source of infection in 12%–43% of patients [15–17]. Consistent
with this finding, the majority of participants reported that the
source of BSI remained unknown in 120% of cases. An un-
defined source of S. aureus bacteremia has been identified as
an independent predictor of 30-day mortality [15]. The timely
delivery of effective antimicrobial therapy is critical for the
successful treatment of S. aureus BSI. Delaying the initiation
of treatment by as little as 45 h from the time of the first blood
culture positive for S. aureus can increase the duration of hos-
pitalization and can increase the risk of infection-related mor-
tality [18]. Therefore, the vast majority of participants did not
delay initiation of therapy in the case of a blood culture positive
for S. aureus with an unknown source of infection. However,
when participants considered blood cultures negative for S.
aureus but positive for another gram-positive organism, the
response was strikingly different, with more than one-half of
the participants reporting that they might delay treatment. An-
tibiotic therapy targeted at simply resolving the bacteremia
alone might not adequately address the underlying infection,
thereby increasing the risk of recurrence, with potentially se-
rious complications. Some participants felt that, for patients
with an underlying infection, it may be beneficial to identify
the source of infection before initiation of therapy if the pa-
tient’s condition remains stable.
Use of an inadequate empirical treatment regimen is known
to have detrimental effects and is associated with higher in-
hospital mortality [18, 19], irrespective of the pathogen or other
risk factors for mortality [20]. It has been suggested that the
selection of empirical treatment regimens for suspected S. au-
reus BSI should be guided by both the local prevalence of MRSA
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infection and the patient’s history [7]. When the factors that
might influence the decision to prescribe empirical anti-MRSA
therapy for a suspected S. aureus infection were considered,
participant opinion was almost equally divided; individual clin-
ical risk factors were key in the decision to initiate empirical
anti-MRSA therapy for 45% of respondents, whereas 39% con-
sidered local epidemiology to be of primary importance.
The participants’ choice of antimicrobial agents for treatment
of S. aureus infections was primarily in accordance with current
UK guidelines that, for reasons of overall patient safety, con-
venience, and cost [21], recommend b-lactams as the preferred
agents for treatment of documented or suspected MSSA in-
fection. This recommendation is supported by 2 large pro-
spective studies. Chang et al. [22] found that patients with
MSSA bacteremia who received vancomycin therapy had a
higher rate of relapse and microbiological failure, compared
with patients who received nafcillin treatment, whereas Stry-
jewski et al. [23] found significantly higher rates of treatment
failure and recurrent infection at 12 weeks after the initiation
of treatment among patients with MSSA bacteremia who re-
ceived vancomycin treatment, compared with patients who re-
ceived cefazolin treatment. Therefore, the use of glycopeptides
for the treatment of MSSA infection is recommended only for
patients who are allergic to penicillins [24]. Guidelines for the
prophylaxis and treatment of MRSA infection in the United
Kingdom recommend glycopeptides as the mainstay of anti-
MRSA therapy, particularly for bacteremia, complicated skin
and soft-tissue infections, and bone infections [21].
The need to update guidelines as new evidence emerges on
the use of recently approved antimicrobial agents has been
acknowledged [21, 25]. Daptomycin is a novel cyclic lipopep-
tide antibacterial agent that has demonstrated efficacy in clinical
trials for the treatment of both MSSA and MRSA complicated
skin and soft-tissue infections and S. aureus bacteremia, with
and without right-sided IE [26, 27]. The results of this con-
sensus conference suggest that daptomycin is now also proving
to be effective in clinical practice.
Uncomplicated BSIs have been characterized by the isolation
of S. aureus from blood cultures of samples from patients with-
out evidence of metastatic spread [27], the absence of sustained
BSI, rapid clinical response (normalization of temperature) to
antibacterial therapy, and the absence of complications within
a given follow-up period [28]. However, such definitions are
usually specific to a particular clinical study, and no definitive
criteria to identify uncomplicated S. aureus bacteremia have
been accepted. The failure of participants to reach consensus
on this issue might reflect the difficulties in superimposing a
definition on a condition with a wide spectrum of clinical
presentations.
An alternative strategy has been to identify patients with good
prognostic features who are thus at low risk of developing
complications of S. aureus bacteremia [7, 28]. In a similar ap-
proach, participants felt that the establishment of criteria to
identify patients who can be treated safely for 14 days was more
important than the definition. This would entail a risk-benefit
assessment incorporating all the stakeholders to balance the
cost of long-term intravenous therapy against the risk of pa-
tients returning with recurrent S. aureus bacteremia or com-
plications such as endocarditis. The established criteria are
comparable to a previously recommended treatment duration
of 10–14 days for S. aureus infection in patients with good
prognostic characteristics (i.e., those who have normal exam-
ination findings, lack a prosthetic device, and are afebrile, with
a negative blood culture result 72 h after presentation) [7].
After some discussion, participants agreed on a 14-day treat-
ment period but cautioned that patients should be followed up
to monitor their condition and to treat any complications that
develop. No specific recommendations regarding the duration
of this follow-up monitoring period were made. However, there
was agreement that the majority of relapses occur within the
first month after treatment. This is at variance with published
data suggesting that the relapse rate generally remains constant
during the first 3 months after treatment [29].
IE is arguably the most common complication associated
with S. aureus BSI. Echocardiography can play a central role
in the diagnosis and management of IE, as evidenced by the
recommendation of the American Heart Association that echo-
cardiography be performed in all cases of suspected IE [30].
Patients may undergo TEE (or transthoracic echocardiogra-
phy), depending on the particular clinical circumstances. Trans-
thoracic echocardiography is less invasive, more widely avail-
able, and easier and cheaper to perform, compared with TEE
[7, 31]. It is typically performed as the first option for patients
at low risk of IE and for patients for whom there is the greatest
likelihood of definitive images (e.g., children and those with a
low body mass index) [30]. TEE has the potential to provide
high-quality images of the heart [31], and it is recommended
for patients for whom clinical suspicion of IE or its compli-
cations is high (i.e., those with staphylococcal bacteremia, pros-
thetic valves, or a new atrioventricular block) or for whom
imaging may be difficult [30]. In addition, TEE was shown to
be a cost-effective method to determine the duration of therapy
for patients with clinically uncomplicated bacteremia [32]. De-
spite these recommendations, fewer than one-half of partici-
pants thought that TEE was necessary to adequately evaluate
the risk of complication.
The clinical consensus conference provided valuable insight
into the opinions and working practices of a range of primarily
European clinicians with an interest in BSIs, particularly those
caused by S. aureus. Outcomes should, however, be interpreted
with recognition that the participants were self-selected and
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that voting was preceded by “state-of-the-art” presentations
from leading experts.
There was consensus on some key aspects regarding the man-
agement of BSIs caused by S. aureus (compared with BSIs
caused by other gram-positive pathogens) and the preferred
treatment regimens for MSSA and MRSA infections. However,
the discussions have highlighted several differences in thera-
peutic approaches to gram-positive infections (particularly
those caused by S. aureus), such as the appropriate treatment
duration and the usefulness of inflammatory markers in the
diagnosis and/or management of BSIs. Definitive evidence-
based guidelines for both the diagnosis and optimal treatment
of S. aureus BSIs are required, and this subject deserves further
study.
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